These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 22585396)
1. Preliminary observations and diagnostic value of lipid peak in ovarian thecomas/fibrothecomas using in vivo proton MR spectroscopy at 3T. Takeuchi M; Matsuzaki K; Harada M J Magn Reson Imaging; 2012 Oct; 36(4):907-11. PubMed ID: 22585396 [TBL] [Abstract][Full Text] [Related]
2. Value of diffusion-weighted imaging combined with conventional magnetic resonance imaging in the diagnosis of thecomas/fibrothecomas and their differential diagnosis with malignant pelvic solid tumors. Yin B; Li W; Cui Y; Chu C; Ding M; Chen J; Zhang P; Wu X World J Surg Oncol; 2016 Jan; 14(1):5. PubMed ID: 26744173 [TBL] [Abstract][Full Text] [Related]
3. MRI features of ovarian fibroma and fibrothecoma with histopathologic correlation. Shinagare AB; Meylaerts LJ; Laury AR; Mortele KJ AJR Am J Roentgenol; 2012 Mar; 198(3):W296-303. PubMed ID: 22358029 [TBL] [Abstract][Full Text] [Related]
4. Magnetic resonance imaging features of ovarian fibroma, fibrothecoma, and thecoma. Chung BM; Park SB; Lee JB; Park HJ; Kim YS; Oh YJ Abdom Imaging; 2015 Jun; 40(5):1263-72. PubMed ID: 25273949 [TBL] [Abstract][Full Text] [Related]
5. Fibroma and fibrothecoma of the ovary: MR imaging findings. Troiano RN; Lazzarini KM; Scoutt LM; Lange RC; Flynn SD; McCarthy S Radiology; 1997 Sep; 204(3):795-8. PubMed ID: 9280262 [TBL] [Abstract][Full Text] [Related]
6. Preliminary observations and clinical value of lipid peak in high-grade uterine sarcomas using in vivo proton MR spectroscopy. Takeuchi M; Matsuzaki K; Harada M Eur Radiol; 2013 Sep; 23(9):2358-63. PubMed ID: 23740024 [TBL] [Abstract][Full Text] [Related]
7. Longitudinally monitoring chemotherapy effect of malignant musculoskeletal tumors with in vivo proton magnetic resonance spectroscopy: an initial experience. Hsieh TJ; Li CW; Chuang HY; Liu GC; Wang CK J Comput Assist Tomogr; 2008; 32(6):987-94. PubMed ID: 19204465 [TBL] [Abstract][Full Text] [Related]
8. Proton magnetic resonance spectroscopy of musculoskeletal lesions at 3 T with metabolite quantification. Lee CW; Lee JH; Kim DH; Min HS; Park BK; Cho HS; Kang HG; Suh JS; Ehara S Clin Imaging; 2010; 34(1):47-52. PubMed ID: 20122519 [TBL] [Abstract][Full Text] [Related]
9. Intracellular lipid in ovarian thecomas detected by dual-echo chemical shift magnetic resonance imaging: report of 2 cases. Okajima Y; Matsuo Y; Tamura A; Irie H; Nakazono T; Hara Y; Suzuki K; Yamasaki F; Kudo S; Saida Y J Comput Assist Tomogr; 2010; 34(2):223-5. PubMed ID: 20351509 [TBL] [Abstract][Full Text] [Related]
10. Histologic and immunohistochemical evidence for considering ovarian myxoma as a variant of the thecoma-fibroma group of ovarian stromal tumors. Costa MJ; Morris R; DeRose PB; Cohen C Arch Pathol Lab Med; 1993 Aug; 117(8):802-8. PubMed ID: 7688213 [TBL] [Abstract][Full Text] [Related]
11. Preliminary study of 3T 1H MR spectroscopy in bone and soft tissue tumors. Qi ZH; Li CF; Li ZF; Zhang K; Wang Q; Yu DX Chin Med J (Engl); 2009 Jan; 122(1):39-43. PubMed ID: 19187615 [TBL] [Abstract][Full Text] [Related]
12. Diffusion-weighted magnetic resonance imaging of ovarian tumors: differentiation of benign and malignant solid components of ovarian masses. Takeuchi M; Matsuzaki K; Nishitani H J Comput Assist Tomogr; 2010; 34(2):173-6. PubMed ID: 20351498 [TBL] [Abstract][Full Text] [Related]
13. Characterization of musculoskeletal lesions on 3-T proton MR spectroscopy. Fayad LM; Barker PB; Jacobs MA; Eng J; Weber KL; Kulesza P; Bluemke DA AJR Am J Roentgenol; 2007 Jun; 188(6):1513-20. PubMed ID: 17515370 [TBL] [Abstract][Full Text] [Related]
14. MR Spectroscopy for Differentiating Benign From Malignant Solid Adnexal Tumors. Ma FH; Qiang JW; Cai SQ; Zhao SH; Zhang GF; Rao YM AJR Am J Roentgenol; 2015 Jun; 204(6):W724-30. PubMed ID: 26001263 [TBL] [Abstract][Full Text] [Related]
15. Preliminary observations and clinical value of N-acetyl resonances in ovarian tumours using in-vivo proton MR spectroscopy at 3T. Takeuchi M; Matsuzaki K; Harada M Eur Radiol; 2011 Dec; 21(12):2640-6. PubMed ID: 21818526 [TBL] [Abstract][Full Text] [Related]
16. In vivo proton spectroscopy of giant cell tumor of the bone. Sah PL; Sharma R; Kandpal H; Seith A; Rastogi S; Bandhu S; Jagannathan NR AJR Am J Roentgenol; 2008 Feb; 190(2):W133-9. PubMed ID: 18212197 [TBL] [Abstract][Full Text] [Related]
17. Contribution of ultrasound in the study of ovarian fibrothecomas: a series of 47 cases. Slimani O; Ben Temim R; Ajroudi M; Makhlouf T; Mathlouthi N; Attia L Tunis Med; 2017 Jan; 95(1):29-36. PubMed ID: 29327766 [TBL] [Abstract][Full Text] [Related]
18. Value of dynamic enhanced magnetic resonance imaging for distinguishing between ovarian fibroma and subserous uterine leiomyoma. Thomassin-Naggara I; Daraï E; Nassar-Slaba J; Cortez A; Marsault C; Bazot M J Comput Assist Tomogr; 2007; 31(2):236-42. PubMed ID: 17414760 [TBL] [Abstract][Full Text] [Related]
19. Evaluation of ovarian tumors by proton magnetic resonance spectroscopy at three Tesla. Stanwell P; Russell P; Carter J; Pather S; Heintze S; Mountford C Invest Radiol; 2008 Oct; 43(10):745-51. PubMed ID: 18791417 [TBL] [Abstract][Full Text] [Related]
20. Ovarian fibromas and fibrothecomas: sonographic correlation with computed tomography and magnetic resonance imaging: a 5-year single-institution experience. Yen P; Khong K; Lamba R; Corwin MT; Gerscovich EO J Ultrasound Med; 2013 Jan; 32(1):13-8. PubMed ID: 23269706 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]